Modified fruquintinib for colorectal cancer with liver metastases
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a modified version of the drug fruquintinib for people with colorectal cancer that has spread to the liver. It is for those who have had successful liver-directed treatment (surgery, ablation, or radiation) and have no signs of cancer left, then finished chemotherapy without the cancer growing back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that spread to your liver.
- You are between 18 and 75 years old.
- You had first-line chemotherapy that controlled your disease (tumor shrank or stayed the same).
- You received local treatment for liver metastases (surgery, ablation, or SBRT) and now have no evidence of cancer (NED).
- You completed adjuvant chemotherapy after achieving NED and had no cancer progression.
- Your last chemotherapy was within the past 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests a new combination of three drugs (fruquintinib, camrelizumab, and capecitabine) for people with colorectal cancer that has spread or cannot be removed and has stopped responding to a standard first chemotherapy. It is for those whose cancer progressed after a specific first treatment called FOLFOXIRI.
This trial tests a new drug called fruquintinib for people with advanced liver cancer who have already tried immunotherapy. It may help shrink tumors or slow cancer growth.
This trial is testing a combination of two oral anti-cancer drugs (fruquintinib and S-1) for people whose metastatic colorectal cancer has not responded to at least two standard treatments. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of three treatments (a drug called QL1706, a targeted therapy called fruquintinib, and a short course of radiation) for people with colorectal cancer that has spread to the liver and has normal DNA repair. The goal is to see if this combination works better than the usual third-line therapy.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.